|
BALTIMORE, Md.—August 15, 2012—Prostate cancer is a highly heterogeneous disease, ranging from slow growth and minimal complications to rapidly progressive disease. A considerable percentage of patients ultimately progress to metastatic castration-resistant prostate cancer (mCRPC), even when treated with intent to cure.
To help oncologists and urologists make decisions on assessment and treatment strategies, Med-IQ, an ACCME-accredited provider of continuing medical education (CME), invites these specialists to participate in a new, complimentary CME course to understand treatment options for mCRPC, review strategies for referring patients with advanced prostate cancer to other specialists, and develop effective communication plans with both patients and specialists.
 New Perspectives in Advanced Prostate Cancer Management for Oncologists and
Urologists: A Report of Current Evidence, National Survey Findings, and In-Practice Research
In 2011, Med-IQ conducted in-practice research with oncologists and urologists to determine current practice patterns, clinical gaps, and educational opportunities related to the assessment and management of mCRPC.
“From this research, we obtained grassroots-level information related to the challenges associated with risk assessment, referral, communication between specialists, treatment considerations, and patient education,” said William A. Mencia, MD, CCMEP, Vice President of Education and Medical Affairs at Med-IQ. “This complimentary CME-certified publication presents these findings within the context of current medical science on the assessment and management of advanced prostate cancer.”
| Faculty |
| |
E. David Crawford, MD
Professor, Surgery, Urology, and Radiation Oncology
Head, Urologic Oncology
University of Colorado
Associate Director
University of Colorado Comprehensive Cancer Center
Denver, CO
|
|
| |
Oliver Sartor, MD
Professor, Department of Medicine and Urology
C.E. and Bernadine Laborde Professor of Cancer Research
Tulane University School of Medicine
Medical Director of the Tulane Cancer Center
New Orleans, LA
|
|
Interested clinicians are invited to learn more by visiting www.Med-IQ.com/a628.
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Med-IQ designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity is supported by an educational grant from Sanofi-aventis U.S. Inc., A SANOFI COMPANY.
For more information, call (toll-free) 866 858 7434, e-mail info@med-iq.com, or visit www.Med-IQ.com/a628.
|
About Med-IQ
Med-IQ, America’s most respected provider of continuing medical education (CME), inspires healthcare professionals through activities that deliver sophisticated outcomes-based educational designs with measurable results in professional competence and performance. Med-IQ received the Alliance for Continuing Education in the Health Professions' President’s Award (2012), Award for Outstanding CME Outcomes Assessment (2012), and William Campbell Felch Award for Outstanding Research in CME (2011). Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the California Board of Registered Nursing (CBRN), and the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing medical education to physicians, nurses, and pharmacists, respectively. We are a leader in the development of performance improvement (PI) and quality improvement (QI) CME initiatives. To learn more about Med-IQ, visit www.Med-IQ.com, like us on Facebook, follow us on Twitter, connect with us on LinkedIn, and visit our YouTube channel.
For more information, contact: |
close
